Researchers from the Institute of Medicinal Biotechnology in China reported the preclinical characterization of a series of benzene sulfonamide derivatives developed as androgen receptor (AR) antagonists.
Researchers from the University of California, Davis have designed a novel gene therapy vector that selectively targets and kills cells infected with Kaposi’s sarcoma-associated herpesvirus (KSHV).
HCW Biologics Inc. has developed second-generation, tissue factor-targeting T-cell engagers (TCEs) to treat solid tumors, particularly pancreatic cancer and glioblastoma, constructed with its novel proprietary TRBC product discovery and development platform technology.
Secreted gonadotropin-releasing hormone (GnRH) acts on the anterior pituitary gland to initiate puberty. Mutations in the protein immunoglobulin superfamily member 10 (IGSF10) have been linked to puberty delay, but the reason has been unclear.
Xtalpi Inc. has announced regulatory clearances in Australia and Taiwan for phase I trials of PEP-08, a next-generation PRMT5 inhibitor candidate developed under its AI drug discovery collaboration with Pharmaengine Inc., for solid tumors. This milestone triggered a payment to Xtalpi under the partnership agreement.
Shanghai Institute of Organic Chemistry and the University of Michigan have prepared and tested new cyclin-dependent kinase 12 (CDK12) and 13 (CDK13) inhibitors reported to be useful for the treatment of cancer.
A Chong Kun Dang Pharmaceutical Corp. patent describes new poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors potentially useful for the treatment of cancer, rheumatoid arthritis, multiple sclerosis, Crohn’s disease, ulcerative colitis, graft-vs.-host disease, systemic lupus erythematosus and osteoarthritis, among others.
Recurium IP Holdings LLC has patented new Wee1-like protein kinase (Wee1) inhibitors and/or degradation inducers reported to be useful for the treatment of cancer.
Immunoglobulin superfamily 11 (IgSF11) overexpression has been observed in several cancer types, including gastric cancer, hepatocellular carcinoma, colorectal cancers and gliomas, and linked to aggressive clinicopathological features. Therefore, IgSF11 has been proposed as a novel immune checkpoint ligand and a candidate for cancer immunotherapy. However, the potential role and clinical significance of IgSF11 in human breast cancer remain unexplored.
Neuronos Ltd., a subsidiary of Beyond Air Inc., has announced the granting of orphan drug designation by the FDA to BA-101 for the treatment of glioblastoma (GBM). The company is advancing development of BA-101 toward first-in-human studies.
RSS
